Suzhou Sanegene Bio

Privately held: no public share price

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 2
Angiotensinogen (AGT)RNA / oligonucleotide
Hypertension
Phase 1
PCSK9 (proprotein convertase subtilisin/kexin type 9) mRNARNA / oligonucleotide
Atherosclerotic Cardiovascular Disease

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2029 (1)
March 2029 (1)
IBI3016Phase 2Hypertension
Est. primary completion 2029-03-27 · NCT07352969 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.